Characteristics of the patients who underwent NIMA-complementary stem cell transplantation, their donors, and the transplantation procedures
. | . | Type of donor . | . | . | ||
|---|---|---|---|---|---|---|
| Characteristics . | Total . | Mother . | Offspring or sibling . | P . | ||
| No. | 35 | 15 | 20 | |||
| Median age of recipient at SCT, y (range) | 28 (2-58) | 18 (3-33) | 42 (2-58) | .007 | ||
| Sex combination: donor/recipient; no. (%) | ||||||
| Female/male | 14 (40) | 10 (67) | 4 (20) | .01* | ||
| Female/female | 13 (37) | 5 (33) | 8 (40) | |||
| Male/male | 3 (9) | - | 3 (15) | |||
| Male/female | 5 (14) | - | 5 (25) | |||
| Diagnosis, no. (%) | ||||||
| AML | 12 (34) | 3 (20) | 9 (45) | NS | ||
| ALL, including LBL | 12 (34) | 7 (47) | 5 (25) | |||
| CML | 7 (20) | 3 (20) | 4 (20) | |||
| DLBCL | 3 (9) | 2 (13) | 1 (5) | |||
| ATL | 1 (3) | 0 (0) | 1 (5) | |||
| Previous SCT, no. (%) | ||||||
| Present: autologous | 2 (6) | 0 (0) | 2 (10) | NS | ||
| Present: allogeneic | 5 (14) | 3 (20) | 2 (10) | |||
| Absent | 28 (80) | 12 (80) | 16 (80) | |||
| Disease status at SCT, no. (%) | ||||||
| In remission or chronic phase | 13 (37) | 4 (27) | 9 (45) | NS | ||
| Chemorefractory | 22 (63) | 11 (73) | 11 (55) | |||
| Type of conditioning, no. (%) | ||||||
| Standard intensity with TBI | 21 (60) | 9 (60) | 12 (60) | NS | ||
| Standard intensity without TBI | 3 (9) | 1 (7) | 2 (10) | |||
| Reduced intensity with ATG | 3 (9) | 2 (13) | 1 (5) | |||
| Reduced intensity without ATG | 8 (23) | 3 (20) | 5 (25) | |||
| Disparity of HLA-A, -B, -DR antigen, no. (%) | ||||||
| GVH direction | NS | |||||
| 2 Ag mismatched | 24 (69) | 10 (67) | 14 (70) | |||
| 3 Ag mismatched | 11 (31) | 5 (33) | 6 (30) | |||
| HVG direction | ||||||
| 0 Ag mismatched | 2 (6) | 2 (13) | 0 (0) | .009 | ||
| 1 Ag mismatched | 3 (9) | 2 (13) | 1 (5) | |||
| 2 Ag mismatched | 16 (46) | 9 (60) | 7 (35) | |||
| 3 Ag mismatched | 14 (40) | 2 (13) | 12 (60) | |||
| Stem cell source, no. (%) | ||||||
| Peripheral blood | 30 (86) | 12 (80) | 18 (90) | NS | ||
| Bone marrow | 4 (11) | 2 (13) | 2 (10) | |||
| Peripheral blood plus bone marrow | 1 (3) | 1 (7) | 0 (0) | |||
| G-CSF after transplantation, no. (%) | ||||||
| Yes | 28 (80) | 12 (80) | 16 (80) | NS | ||
| No | 7 (20) | 3 (20) | 4 (20) | |||
| GVHD prophylaxis, no. (%) | ||||||
| Tacrolimus alone | 4 (11) | 0 (0) | 4 (20) | NS | ||
| Tacrolimus plus MMF or corticosteroids | 2 (6) | 2 (13) | 0 (0) | |||
| Tacrolimus plus MTX | 23 (66) | 10 (67) | 13 (65) | |||
| Tacrolimus plus MTX plus corticosteroids | 6 (17) | 3 (20) | 3 (15) | |||
. | . | Type of donor . | . | . | ||
|---|---|---|---|---|---|---|
| Characteristics . | Total . | Mother . | Offspring or sibling . | P . | ||
| No. | 35 | 15 | 20 | |||
| Median age of recipient at SCT, y (range) | 28 (2-58) | 18 (3-33) | 42 (2-58) | .007 | ||
| Sex combination: donor/recipient; no. (%) | ||||||
| Female/male | 14 (40) | 10 (67) | 4 (20) | .01* | ||
| Female/female | 13 (37) | 5 (33) | 8 (40) | |||
| Male/male | 3 (9) | - | 3 (15) | |||
| Male/female | 5 (14) | - | 5 (25) | |||
| Diagnosis, no. (%) | ||||||
| AML | 12 (34) | 3 (20) | 9 (45) | NS | ||
| ALL, including LBL | 12 (34) | 7 (47) | 5 (25) | |||
| CML | 7 (20) | 3 (20) | 4 (20) | |||
| DLBCL | 3 (9) | 2 (13) | 1 (5) | |||
| ATL | 1 (3) | 0 (0) | 1 (5) | |||
| Previous SCT, no. (%) | ||||||
| Present: autologous | 2 (6) | 0 (0) | 2 (10) | NS | ||
| Present: allogeneic | 5 (14) | 3 (20) | 2 (10) | |||
| Absent | 28 (80) | 12 (80) | 16 (80) | |||
| Disease status at SCT, no. (%) | ||||||
| In remission or chronic phase | 13 (37) | 4 (27) | 9 (45) | NS | ||
| Chemorefractory | 22 (63) | 11 (73) | 11 (55) | |||
| Type of conditioning, no. (%) | ||||||
| Standard intensity with TBI | 21 (60) | 9 (60) | 12 (60) | NS | ||
| Standard intensity without TBI | 3 (9) | 1 (7) | 2 (10) | |||
| Reduced intensity with ATG | 3 (9) | 2 (13) | 1 (5) | |||
| Reduced intensity without ATG | 8 (23) | 3 (20) | 5 (25) | |||
| Disparity of HLA-A, -B, -DR antigen, no. (%) | ||||||
| GVH direction | NS | |||||
| 2 Ag mismatched | 24 (69) | 10 (67) | 14 (70) | |||
| 3 Ag mismatched | 11 (31) | 5 (33) | 6 (30) | |||
| HVG direction | ||||||
| 0 Ag mismatched | 2 (6) | 2 (13) | 0 (0) | .009 | ||
| 1 Ag mismatched | 3 (9) | 2 (13) | 1 (5) | |||
| 2 Ag mismatched | 16 (46) | 9 (60) | 7 (35) | |||
| 3 Ag mismatched | 14 (40) | 2 (13) | 12 (60) | |||
| Stem cell source, no. (%) | ||||||
| Peripheral blood | 30 (86) | 12 (80) | 18 (90) | NS | ||
| Bone marrow | 4 (11) | 2 (13) | 2 (10) | |||
| Peripheral blood plus bone marrow | 1 (3) | 1 (7) | 0 (0) | |||
| G-CSF after transplantation, no. (%) | ||||||
| Yes | 28 (80) | 12 (80) | 16 (80) | NS | ||
| No | 7 (20) | 3 (20) | 4 (20) | |||
| GVHD prophylaxis, no. (%) | ||||||
| Tacrolimus alone | 4 (11) | 0 (0) | 4 (20) | NS | ||
| Tacrolimus plus MMF or corticosteroids | 2 (6) | 2 (13) | 0 (0) | |||
| Tacrolimus plus MTX | 23 (66) | 10 (67) | 13 (65) | |||
| Tacrolimus plus MTX plus corticosteroids | 6 (17) | 3 (20) | 3 (15) | |||
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia; LBL, lymphoblastic lymphoma; CML, chronic myeloid leukemia; DLBCL, diffuse large B-cell lymphoma; ATL, adult T-cell leukemia/lymphoma; TBI, total-body irradiation; ATG, antithymocyte globulin, Ag, antigen; MMF, mycophenolate mofetil; MTX, methotrexate; and NS, statistically nonsignificant.
Comparison between female-into-male pairs and the other combinations